This page in Swedish

Research projects


About this project

Project information

Project status

In progress


Jonas Halfvarson

Research subject

Many patients with autoimmune, inflammatory and allergic diseases do not respond well or at all to current treatments. A major challenge for researchers is to understand which patients are most likely to respond to which treatments. The aim of 3TR is to shed new light on the factors that determine whether or not a patient is likely to respond to a given treatment. 3TR will focus on seven diseases: systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, ulcerative colitis, Crohn’s disease, asthma, and chronic obstructive pulmonary disease (COPD). Despite their diverse symptoms, these diseases have some molecular patterns in common, suggesting that patients with different diseases may share some markers that predict the likelihood of treatment response and disease progression.

The project will analyse data and samples from 50 000 patients who took part in 50 clinical trials. They will also carry out a new clinical study that will take samples (of diseased tissue, blood, stool and other fluids) from patients before, during and after treatment. The project will add all of its data to a centralised data management platform that will make it easier to analyse using state-of-the-art methods. The samples collected and the knowledge base will be maintained beyond the end of the project to allow further research. The project will ultimately make it easier to provide the right treatment to the right patient, thereby increasing the proportion of patients taking a treatment that works for them.

Research funding bodies

  • EU Horizon 2020
  • IMI innovative medicines initiative


  • Åsa Kälvesten, Kliniskt forskningscentrum HS